← Back to Clinical Trials
Recruiting NCT06968312

Hexadecanal as an Addon to Cognitive Processing Therapy for PTSD

Trial Parameters

Condition Post Traumatic Stress Disorder (PTSD)
Sponsor Tel Aviv University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 40
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-05-05
Completion 2026-09-30
Interventions
Cognitive Processing Therapy + HexadecanalHexadecanal - Molecule Distribution in the Therapy room

Brief Summary

This RCT investigates whether Cognitive Processing Therapy, a first line treatment for PTSD, can be enhanced by the use of the odor molecule Hexadecenal (HEX). HEX is secreted from body odor and has been shown to promotes psychological well-being and positive social interaction. For the active group Hex will be diffused in the treatment room during all treatment sessions. For the control group a vehicle placebo molecule will be diffused. Both therapists and patients will be blind to study condition.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of PTSD according to DSM-5 * Age 18 years and over * Eligible for CPT treatment at the National Center for Traumatic Stress and Resilience Exclusion Criteria: * Bipolar disorder, psychosis, neurological disorders * Drug Addiction * Parallel psychotherapy * Congenital or acquired anosmia.

Related Trials